Hackensack Meridian Health launched a clinical trial with Israeli startup SpotitEarly, which is developing a cancer test that combines AI with trained dogs to analyze patients' breath. The study aims to validate this noninvasive approach alongside traditional screenings, potentially enabling earlier and more accessible cancer detection.
Hackensack Meridian Health launched a clinical trial with Israeli startup SpotitEarly, which is developing a cancer test that combines AI with trained dogs to analyze patients' breath. The study aims to validate this noninvasive approach alongside traditional screenings, potentially enabling earlier and more accessible cancer detection.
Veradigm Senior Solutions Manager, Will Barnett talks about the health tech vendor's clearinghouse services and how they manage the relationship between payers and providers in support of evidence-based care and value-based care strategies. Learn more.
Visana Health's Series A round was led by Noro-Moseley Partners and included participation from The Cigna Group Ventures, Intermountain Ventures, Flare Capital Partners and Frist Cressey Ventures.
Novartis drug Rhapsido is now approved as a second-line treatment for chronic spontaneous urticaria, a rare inflammatory skin disease. Additional clinical trials are ongoing to support potential expansion of the twice-daily pill to other immunological disorders.
Daniel Karlin, chief medical officer of MindMed, spoke at DiMe's Healthcare 2030 Summit in Washington, D.C. His company is developing novel treatments for brain health disorders, with a focus on psychiatry, neurology and addiction.
Karlin urged healthcare leaders to look beyond existing data and assumptions to create more meaningful, systemic improvements.
The best assistive devices for children with sensory processing disorders are those that meet their needs. They will enhance their ability to participate more fully in daily activities.
The latest episode of the Debunked podcast explores an ongoing debate questioning the role of payers in healthcare transactions. It also highlights turmoil at the CDC.
No comments